Pages that link to "Q36265931"

The following pages link to Benefit-risk assessment of levetiracetam in the treatment of partial seizures (Q36265931):

Displaying 18 items.

• Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures (Q24650880) (← links)
• Self-reported feelings of anger and aggression towards others in patients on levetiracetam: data from the UK antiepileptic drug register (Q30604685) (← links)
• Levetiracetam, phenytoin, and valproate act differently on rat bone mass, structure, and metabolism (Q33290977) (← links)
• Update: new uses for lithium and anticonvulsants (Q34710521) (← links)
• A new mechanism for antiepileptic drug action: vesicular entry may mediate the effects of levetiracetam (Q35217702) (← links)
• The safety of levetiracetam (Q36811528) (← links)
• Rapid dosage titration of levetiracetam in children (Q37092273) (← links)
• Use of second-generation antiepileptic drugs in the pediatric population (Q37203259) (← links)
• Assessing the unmet treatment need in partial‐onset epilepsy: Looking beyond seizure control (Q37802905) (← links)
• Psychosocial difficulties in people with epilepsy: a systematic review of literature from 2005 until 2010. (Q38022986) (← links)
• Implications of pharmacogenetics for the therapeutic use of antiepileptic drugs (Q38181565) (← links)
• Genetic variation in dopaminergic activity is associated with the risk for psychiatric side effects of levetiracetam (Q39571405) (← links)
• Levetiracetam extended release and levetiracetam immediate release as adjunctive treatment for partial-onset seizures: an indirect comparison of treatment-emergent adverse events using meta-analytic techniques (Q43287918) (← links)
• Positive and negative psychotropic effects of levetiracetam (Q46516531) (← links)
• Levetiracetam for the treatment of hot flashes: a phase II study (Q48463682) (← links)
• Efficacy of mGlu2 -positive allosteric modulators alone and in combination with levetiracetam in the mouse 6 Hz model of psychomotor seizures (Q51150507) (← links)
• Adjunctive eslicarbazepine acetate: A pooled analysis of three phase III trials. (Q53782575) (← links)
• Psychiatric and cognitive adverse events: A pooled analysis of three phase III trials of adjunctive eslicarbazepine acetate for partial-onset seizures (Q57040428) (← links)